managed care, healthcare, cancer, melanoma, hospice, ipilimumab, vemurafenib, metastatic, survival rates, end-of-life, healthcare costs, Affordable Care Act, patient-centered, palliative care


More Hospice Care Meant Longer Survival, Lower End-of-Life Costs for Metastatic Melanoma Patients

May 23, 2014

A study in The American Journal of Managed Care found that longer stays in hospice were associated with longer survival and lower end-of-life costs for patients with metastatic melanoma, a particularly deadly and increasingly common form of cancer.